Citadel Advisors
CUE icon

Citadel Advisors’s Cue Biopharma CUE Stock Holding History

Citadel Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Buy
+25,633
New +$580K ﹤0.01% 8727
2024
Q3 		– Sell
-2,776
Closed -$60.1K – 14361
2024
Q2 		$103K Sell
2,776
-2,099
-43% -$104K ﹤0.01% 10867
2024
Q1 		$276K Buy
4,875
+3,181
+188% +$224K ﹤0.01% 9639
2023
Q4 		$134K Sell
1,694
-1,613
-49% -$115K ﹤0.01% 10565
2023
Q3 		$228K Buy
3,307
+1
+0% +$98 ﹤0.01% 9663
2023
Q2 		$362K Sell
3,306
-216
-6% -$25.4K ﹤0.01% 8641
2023
Q1 		$377K Buy
3,522
+2,988
+560% +$285K ﹤0.01% 8888
2022
Q4 		$45.7K Buy
+534
New +$48.8K ﹤0.01% 12248
2022
Q3 		– Sell
-6,801
Closed -$585K – 12758
2022
Q2 		$508K Buy
6,801
+6,389
+1,551% +$747K ﹤0.01% 8602
2022
Q1 		$60K Sell
412
-300
-42% -$63.6K ﹤0.01% 12676
2021
Q4 		$242K Buy
+712
New +$275K ﹤0.01% 11432
2021
Q3 		– Sell
-725
Closed -$253K – 13890
2021
Q2 		$253K Buy
+725
New +$281K ﹤0.01% 11667
2021
Q1 		– Sell
-928
Closed -$382K – 13225
2020
Q4 		$348K Sell
928
-6,320
-87% -$2.53M ﹤0.01% 8804
2020
Q3 		$3.27M Sell
7,248
-1,848
-20% -$1.06M ﹤0.01% 3841
2020
Q2 		$6.69M Buy
9,096
+8,462
+1,335% +$6.13M ﹤0.01% 2692
2020
Q1 		$270K Buy
+634
New +$307K ﹤0.01% 7511

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Citadel Advisors's CUE Position: Q2 2026 in Review

Citadel Advisors opened a new position in Cue Biopharma (CUE) in Q2 2026: 25,633 shares worth $809K. The stake represents ﹤0.01% of the portfolio and ranks #8727 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CUE as recently as Q2 2024.

Citadel Advisors first reported a position in CUE in Q1 2020 and has held it in 16 quarters since. The position peaked at $6.69M in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Citadel Advisors held 25,633 shares of Cue Biopharma worth $809K as of Q2 2026.
  • Cue Biopharma was a new Citadel Advisors position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8727 holding.
  • Citadel Advisors first reported a position in Cue Biopharma in Q1 2020 and has held it in 16 quarters since.
  • Citadel Advisors's Cue Biopharma position peaked at $6.69M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.